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Background: It is mandatory to confirm the absence of mutations in the KRAS gene before treating metastatic
colorectal cancers with epidermal growth factor receptor inhibitors, and similar regulations are being considered for
non-small cell lung carcinomas (NSCLC) and other tumor types. Routine diagnosis of KRAS mutations in NSCLC is
challenging because of compromised quantity and quality of biological material. Although there are several
methods available for detecting mutations in KRAS, there is little comparative data regarding their analytical
performance, economic merits, and workflow parameters.
Methods: We compared the specificity, sensitivity, cost, and working time of five methods using 131 frozen NSCLC
tissue samples. We extracted genomic DNA from the samples and compared the performance of Sanger cycle
sequencing, Pyrosequencing, High-resolution melting analysis (HRM), and the Conformité Européenne (CE)-marked
TheraScreen DxS and K-ras StripAssay kits.
Results and conclusions: Our results demonstrate that TheraScreen DxS and the StripAssay, in that order, were
most effective at diagnosing mutations in KRAS. However, there were still unsatisfactory disagreements between
them for 6.1% of all samples tested. Despite this, our findings are likely to assist molecular biologists in making
rational decisions when selecting a reliable, efficient, and cost-effective method for detecting KRAS mutations in
heterogeneous clinical tumor samples.
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At present, identifying targeted anticancer treatment
suitable for a given patient requires the availability of ac-
curate diagnostics. Diagnostic techniques therefore have
a significant impact on patients’ survival and quality of
life [1]. In recent years, it has become apparent that cer-
tain types of tumors undergo mutations that either ori-
ginate from the aberrant physiology of the tumor or are
induced/selected by mutagenic cancer therapies [2-4].
Failure to detect mutations in important regulatory
genes in tumor specimens may have serious conse-
quences for the patients, because these alterations can
significantly reduce the effectiveness of certain biological
and cytotoxic therapies. Mutations in the KRAS onco-
gene are often found in human cancers. They are most
common in pancreatic cancer, which can exhibit muta-
tion rates of 80 - 90%. KRAS mutations are also
observed in 40 – 50% of colorectal cancers and 10 - 30%
of Non-Small Cell Lung Cancers (NSCLCs).
Recent studies have shown that some anticancer
drugs are only effective against tumors in which the
KRAS signaling pathway has not undergone oncogenic
activation. These include the small-molecule epidermal
growth factor receptor inhibitors erlotinib (TarcevaW)
and gefitinib (IressaW), which are used to treat NSCLC
patients, and monoclonal antibody therapies such as
cetuximab (ErbituxW) and panitumumab (VectibixW),
which are primarily used in the treatment of metastatic
colorectal cancers (mCRC) [5-7]. According to the U.S.
National Comprehensive Cancer Network (NCCN)
guidelines from November 2008 (http://www.nccn.org/
about/news/newsinfo.asp?NewsID=194) and recommen-
dations of the American Society of Clinical Oncology
(ASCO)[8], screening of the status of the KRAS gene is
mandatory when deciding whether or not a patient with
colorectal cancer should receive anti-EGFR drugs. Simi-
lar rules are being considered for NSCLC where KRAS
mutations have prognostic value for progressive disease
in adenocarcinoma [9,10].
There are multiple methods for detecting KRAS muta-
tions in patient tissues, with varying analytical parameters.
Individual methods need to be evaluated in terms of their
sensitivity, specificity, and cost per analysis before they
can be considered to meet acceptable gold standards in
clinical practice. A standardized European quality assur-
ance program for tests to detect mutations in KRAS was
proposed at the Third International Congress of Path-
ology, held by the European Society of Pathology (ESP) in
Barcelona in May 2008. This program is focused on
achieving optimal accuracy and proficiency across the
European Union [11]. However, there are many methods
in current use, some of which are only employed by indi-
vidual laboratories and are not commercially available.
These typically include sequencing assays [12] and gel-based DNA conformation assays [13,14]. Some of the
commercial assays for detecting mutations in the KRAS
gene have not yet been validated for clinical use
(i.e.: Allele-specific oligonucleotide hybridization - Invi-
geneW, KRAS mutation test kit - EntroGenW). At the
time of writing, only the TheraScreenW kit sold by Qia-
Gen, the KRAS LightMixW kit sold by TIB MolBiol, and
the K-ras StripAssayW sold by ViennaLab had received
the Conformité Européenne (CE) mark certifying them
as being suitable for diagnostic use in the clinic under
the terms of the European IVD Directive 98/79/EC.
In order to assess the specificity, sensitivity, cost, and
working time of five frequently used methods for detect-
ing mutations in KRAS, we performed parallel tests
using DNA extracted from 131 frozen NSCLC tissue
samples. The methods examined were Sanger cycle se-
quencing, Pyrosequencing, High-resolution melting ana-
lysis (HRM), and the CE-marked TheraScreen DxS and
K-ras StripAssay kits. Our data demonstrate that there
are important differences between these methods, which




The experimental research presented in this manuscript
was performed in compliance with the Helsinki Declar-
ation according to the study ethics proposal approved by
Ethical Board of Palacky University in Olomouc. Written
informed consent was obtained from all patients for the
use of the collected samples in the research projects
which includes studies for publication of this report or
any accompanied images.
Diagnosis of NSCLC was initially performed at the
time of surgery and later confirmed from leftover by
histological subtyping performed by experienced path-
ologist. All samples were found to contain more than
70% of tumour cells from at least 200 cells.
DNA extraction from cell lines and primary tumor
samples
Genomic DNA was extracted from 131 frozen Non
Small Cell Lung Cancer (NSCLC) tissue specimens
removed from patients undergoing surgery for lung can-
cer. Tissue was snap frozen in liquid nitrogen immedi-
ately after surgery and stored at −80°C until analyzed.
Cell lines with specific KRAS mutations were obtained
from the American Tissue Culture Collection (ATCC,
Rockville, MA) and cultured according to ATCC instruc-
tions. DNA extraction and purification was performed
using the QIAquick (QIAGEN, Hilden, Germany) isolation
kit according to manufacturer´s instructions; in each case
examined, the five methods were tested against the same
DNA isolate, so potential differences in percentage of
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Concentrations of DNA samples were measured spectro-
photometrically using a NanoDrop ND 1000 spectropho-
tometer (NanoDropTechnologies, Wilmington, USA).
Genotyping methods
Analyses were performed according to a blinded design, in
which the experimentalist was not aware of the KRAS mu-
tation status of any given sample. 131 NSCLC samples
were analyzed using four methods: Direct sequencing,
Pyrosequencing, and the TheraScreen DxS and K-ras Stri-
pAssay kits. Due to limited amount of tissue, only 116
samples from this group were also subjected to HRM ana-
lysis and 114 yielded usable data. Significance of the con-
cordance of mutation detection with different methods for
two categories (wildtype and mutant) was assessed by κ
statistics (http://faculty.vassar.edu/lowry/kappa.html).
Direct sequencing method
Two primers were used to prepare amplicons for use in
Sanger dideoxy termination sequencing [15]: a forward
(FW) primer, 5'AAA AGG TAC TGG TGG AGT ATT
TGA, and a 3’ reverse (REV) primer, 5' TCA TGA AAA
TGG TCA GAG AAA CC 3' (Generi-Biotech, Hradec
Králové, Czech Republic). PCR was performed with a
reaction volume of 50 μl in an MJ Research PTC-200
Peltier Thermal Cycler (Watertown, USA). The compos-
ition of the PCR reaction mixture was as follows:
MgCl2 (3 mM, ThermoScientific, Waltham, USA), dNTPs
(0.2 mM, ThermoScientific), ThermoStart DNA polymer-
ase (2U, ThermoScientific), FW-primer (0.3 μM), REV-
primer (0.3 μM), 1xPCR buffer, and between 10 ng and
100 ng of genomic DNA per reaction. The following
amplification program was used: 95°C/15 min to acti-
vate the Taq polymerase; 35x (95°C/30 s, 58°C/30 s
72°C/30 s) for denaturation, annealing, and extension; and
finally 75°C/5 min to finalize the extension, followed by
cooling to 15°C. The PCR product was separated using a
2% agarose gel and purified using the QIAquick PCR puri-
fication kit (QIAGEN, Hilden, Germany). For each sample
specimen, separate sequencing reactions were performed
using the forward (FW) and reverse (REV) primers. The
sequencing primers were internal to the amplicons from
the previous PCR cycles: FW - 5' TTA ACC TTA TGT
GTG ACA TGT TCT AA 3', REV - 5' AGA ATG GTC
CTG CAC CAG TAAT 3'. Sequencing reactions were per-
formed according to the manufacturer´s protocol in a
20 μl reaction volume containing 4 μl DTCS Quick Start
kit (Beckman Coulter, Brea, USA), 1 μl (10 μM) of the
FW or REV primer, 10 μl nuclease-free water, and 5 μl
of 25x diluted template PCR product. After cleaning,
precipitated DNA was diluted in SLS-formamide
(Beckman Coulter, Brea, USA) and dideoxylabelled frag-
ments were size-separated using an automated CEQ8800 Genetic Analysis System (Beckman Coulter, Brea,
USA) (Figure 1). Sequence identification was performed
using version 1.42 of the Chromas software package
(Conor McCarthy, Southport, Australia). For all analyses,
data obtained with the forward and reverse primers were
combined and aligned to the consensus sequence




In the pyrosequencing method for DNA sequence ana-
lysis [16,17], inorganic phosphate released in the course
of nucleotide incorporation serves as the initial substrate
in a sequence of four successive enzymatic reactions.
This result in the emission of light, which functions as a
signal that is proportional to the number of nucleotides
incorporated.
In this project, the PyroMark K-ras assay test (Biotage,
Uppsala, Sweden) was used for primary amplification
and pyrosequencing of both the 12th and the 13th
codons of the KRAS oncogene (Figure 2). The following
amplification program was used: the mixture was heated
at 95°C for 5 min, then subjected to 45 cycles of 95°C
for 15 s, 57°C for 30 s, and 72°C for 15 s. It was then
held at 72°C for 5 min, and finally cooled to and held at
4°C. The final concentrations of the PCR components
were: 1x PCR buffer, 2 mM MgCl2, 0.125 mM dNTPs,
0.2 μM FW primer and 0.2 μM REV biotinylated primer,
1U of AmpliTaq polymerase (Perkin Elmer, Waltham,
USA) and 2 ng/μl DNA template. Fifteen μl of the PCR
product was run on a 1,5% agarose gel (Sigma-Aldrich,
St. Louis, USA) to confirm successful amplification, and
100 ng of PCR products were sent to the EpigenDX
company (Worcester, USA) to be analyzed using the
PyroMark MD System and the Pyromark ID analysis
Software with previously validated cut-off of 5%.
K-RAS TheraScreen DxS
The TheraScreen DxS KRAS Mutation Kits KR-21 and
KR-22 (QiaGen, Hilden, Germany) are designed to detect
six mutations in codon 12 (Gly >Ala, Asp, Arg, Cys, Ser,
and Val) and one in codon 13 (Gly >Asp) of the KRAS
oncogene. The primers used in the assay have two charac-
teristic features: sequence-specific 3´ ends (which com-
prise the PCR-Amplification Refractory Mutation System,
PCR-ARMSW) to identify specific mutations, and Real-
time PCR-ScorpionW primer tags, which fluoresce when
incorporated into double-stranded DNA (Figure 3).
The commercial test kit includes an internal reaction con-
trol and a synthetic control template. The degree of muta-
tion of KRAS is calculated on the basis of the difference
between the control reaction and the allele-specific reac-
tion in terms of the number of cycles required for the
Figure 1 Sequencing of the KRAS gene in DNA isolated from NSCLC tissues. (A) Wild type-(12Gly-GGT, 13Gly-GGC), (B) Mutant- (12Asp-GAT).
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ground level (Δ-CT) [18].
PCR reactions were performed according to the pro-
tocol recommended by the manufacturer (TheraScreen
K-RAS Mutation Kit version DU001PE) using a LightCy-
clerW480 II (Roche Applied Science, Penzberg, Germany),
with a final reaction volume of 25 μl. An initial denatur-
ation step at 95°C for 4 min was followed by 45 cycles of
95°C for 30 sec and 60°C for 1 min. Analysis was
performed using a predefined absolute quantification
algorithm implemented in the LightCycler Analysis
Software 1.5.0 SP3 program (Roche Applied Science,
Penzberg, Germany) and by visual inspection conducted
by two different researchers.
K-ras StripAssay
The K-ras StripAssay REF 5–590 (ViennaLab Diagnostics
GmbH, Vienna, Austria) detects the 10 most common
mutations in the KRAS gene by using multiplex mutant-
enriched PCR and reverse-hybridization of the amplifica-
tion products to nitrocellulose test strips (oligonucleotides
used in the subsequent hybridization reactions are synthe-
sized as probes targeting 8 mutations in codon 12 of the
KRAS gene (Gly >Ala, Arg, Asp, Cys, Ile, Leu, Ser, andVal) and two mutations in codon 13 (Gly >Asp and Gly >
Cys). Specifically hybridized biotinylated oligonucleotides
are visualized using streptavidin-alkaline phosphatase and
colored substrates (Figure 4).
The KRAS StripAssay was performed according to the
manufacturer’s protocol (K-ras StripAssay™, ViennaLab
Diagnostic GmbH, Vienna, Austria). Samples were diluted
using deionized water to a concentration of 10 ng/μl. Five
μl of diluted DNA was added to the multiplex PCR reac-
tion with biotinylated primers, and PCR was conducted
according to the manufacturer’s instructions. All of the
incubation steps were performed using a PST-60 HL Plus
thermoshaker (Biosan, Riga, Latvia) platform with the
temperature set to 45°C. Scanning was performed using
the EPSON Perfection V30 scanner (Epson America, Inc.,
Long Beach, USA) and bands were analyzed by StripAs-
sayEvaluator software (ViennaLab, Vienna, Austria) and
by visual inspection.
High resolution melting analysis
The high-resolution melting (HRM) assay is a platform
for real time detection of mutations that can be used to
identify small differences in DNA sequences, even in
heterozygous samples, by assessing changes in the shape
Figure 2 Pyrosequencing of the KRAS gene in DNA isolated from NSCLC tissues. (A) Wild type-(12Gly-GGT, 13Gly-GGC), (B) Mutant-KRAS
(12Cys-TGT).
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erated using standard (wild-type) DNA [19] (Figure 5).
The HRM assay was developed using a new family of
DNA-intercalating dyes including SYTO 9, LC Green
and LC GreenPLUS+ that display strong intercalation and
even association with DNA.
HRM-PCR reaction components were used accord-
ing to the instructions provided with the LightCyclerW
480 II (Roche) instrument. The LC GreenPLUS (Idaho
Technology, Salt Lake City, USA) intercalating dye was
used, together with the primers FW-5'-AAA CTT
GTG GTA GTT GGA GCT-3' (forward) and REV-5'-
ATT AGC TGT ATC GTC AAG GCA-3' (reverse).
The final concentrations of the components of the re-
action mixture were: 1x PCR buffer, 2 mM MgCl2,
0.2 μM dNTP, 0.5x LC GreenPLUS, 0.2 U ThermoTaq
polymerase (Thermo Scientific), and 0.3 μM FW and
REV primer. The cycling and melting conditions were
as follows: one cycle at 95°C for 15 min., followed by
45 cycles of 95°C for 10 s, 63°C for 10 s, and 72°C for
10 s. The sample was then melted by raising the
temperature from 60°C to 95°C at a rate of 0.02 C/s.
Mutations were analyzed using LightCycler Analysis
Software 1.5.0 SP3 program (Roche Applied Science,
Penzberg, Germany).Results
Five genotyping methods for determining the status of
mutation of KRAS were assessed using frozen tissue
from primary NSCLC tumor specimens. 131 DNA sam-
ples were analyzed with 4 of the methods (Direct se-
quencing, K-ras StripAssay, TheraScreen DxS, and
Pyrosequencing), and 116 of these were also analyzed
using the High resolution melting (HRM) technique. In
the absence of a gold standard, we adopted a consensus
method for assigning each sample’s mutation status. The
results obtained and methodology used are shown in
Table 1.
As expected, the percentage of the DNA samples in
which mutations were detected varied (from 20% to 5%)
depending on the method of detection used. The Kras-
StripAssay had the highest likelihood of referring a mu-
tation in the KRAS locus, followed by TheraScreen DxS,
HRM, Pyrosequencing, and Direct sequencing (Table 2).
However, on the basis of our evaluation criteria (Table 1),
the most sensitive tool was the TheraScreen DxS kit
(95%), followed by the K-ras StripAssay (90%), HRM
(70%), Pyrosequencing (48%), and Sequencing (29%). The
most specific tools were the TheraScreen DxS kit, Sequen-
cing, and Pyrosequencing (100%), followed by HRM (98%)
and the K-ras StripAssay (95%) (Table 3).
Figure 3 TheraScreen analysis of the KRAS gene in DNA isolated from NSCLC tissue. (A) Wild type. The figure shows a positive PCR control
in which the quantity and quality of the DNA were assessed (red curve) without any other amplification of ARMS mutation positive primers
(green curve) (B) Mutant. The figure shows a positive PCR control and a mutation signal (12Asp) generated by one tube of the ARMS-primers.
The upper limit on ΔCt, which corresponds to a mutant DNA content of 1%, is for the mutant PCR to be 8 cycles behind the control PCR (here
ΔCt = 26.44 - 24.03 = 2.41).
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obtained with each method would change if one were to
change the interpretation criteria. For example, if the
K-ras StripAssay is taken to be the gold standard, then
the false positives detected by this method would be-
come false negatives detected by the other methods. To
eliminate this potential ambiguity, we performed more
tests to assess and compare the sensitivity thresholds ofthe tested methods. We used three ATCC cell lines
whose KRAS mutation statuses are known and
recorded in the COSMIC database: A549 (p.Gly12Ser),
NCI-H620 (p.Gly12Val), and NCI-H2009 (p.Gly12Ala).
We extracted sample DNA from the cell lines, measured
its concentration by spectrophotometry, and then made
dilution series of the DNA from the KRAS mutant cell
lines in DNA from the NCI-H1975 KRAS wild-type cell
Figure 4 StripAssay analysis of the KRAS gene in DNA isolated from NSCLC tissue. (A) Wild type-(12Gly, 13Gly) (B) Mutant-(12Ala, 13Gly).
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15%, 10%, 5%, 1%, 0.5%, 0.25%, or 0.125% of the total
KRAS DNA (Figure 6).
At a mutant minority of 1%, only TheraScreen and
StripAssay were capable of detecting mutations in KRAS,Figure 5 HRM melting profile result of the KRAS gene isolated from N
(using the LC GreenPLUS dye with the sensitivity set to 0.3) of wild type sam
yellow colours).while other methods have detection limit at 10% (Pyro-
sequencing), and 25% (HRM and Sanger sequencing).
Interestingly, in one technical replicate the mutation
detected by the TheraScreen DxS kit in cell line A549
(p.Gly12Cys) was inconsistent with what was actuallySCLC tissue. The figure shows the results of Gene Scanning analyses
ples (yellow line) and mutant cell line samples (curves with other than
Table 1 Summary of the genotyping results obtained with the five tested methods in 131 NSCLC samples
DNA sample number Direct sequencing Pyrosequencing TheraScreen DxS K-ras StripAssay HRM Consensus
1 12Cys 12Cys 12Cys 12Cys Mutation 12Cys
2 13Cys 13Cys Wt 13Cys Mutation 13Cys
3 12Cys 12Cys 12Val Wt Mutation 12Cys
4 12Asp 12Asp 12Asp 12Asp Mutation 12Asp
5 12Cys 12Cys 12Cys 12Cys Mutation 12Cys
6 12Cys 12Cys 12Cys 12Cys Mutation 12Cys
7 Wt 12Cys 12Cys 12Cys Mutation 12Cys
8 Wt 12Val 12Val 12Val Mutation 12Val
9 Wt 12Cys 12Cys 12Cys Mutation 12Cys
10 Wt 12Cys 12Cys 12Cys Wt 12Cys
11 Wt Wt 12Cys 12Cys Wt 12Cys
12 Wt Wt 12Cys 12Cys Wt 12Cys
13 Wt Wt 12Val 12Val Wt 12Val
14 Wt Wt 12Cys 12Cys Wt 12Cys
15 Wt Wt 12Cys 12Cys Wt 12Cys
16 Wt Wt 12Arg 13Cys Inconclusive Mutation
17 Wt Wt 12Cys 12Cys Mutation 12Cys
18 Wt Wt 12Asp 13Asp Not tested Mutation
19 Wt Wt 12Asp Wt Mutation 12Asp
20 Wt Wt 12Cys Wt Not tested Inconclusive
21 Wt Wt 13Asp Wt Not tested Inconclusive
22 Wt Wt Wt 12Cys Mutation 12Cys
23 Wt Wt Wt 12Cys Mutation 12Cys
24 Wt Wt Wt 12Arg Wt Wt
25 Wt Wt Wt 12Val Wt Wt
26 Wt Wt Wt 12Cys Wt Wt
27 Wt Wt Wt 13Cys Wt Wt
28 Wt Wt Wt 12Ala,13Cys Wt Wt
29 Wt Wt Wt 12Ser Not tested Inconclusive
30 Wt Wt Wt 12Ala Wt Wt
31 Wt Wt Wt Wt Mutation Wt
32 Wt Wt Wt Wt Mutation Wt




The consensus result for a given sample was taken to be that obtained when the two CE-marked methods (K-ras StripAssay and TheraScreen DxS) were
concordant with one-another (results that do not match this consensus are highlighted with a dark background). The detection of different types of mutation by
different methods (e.g. in sample 3, p.Gly12Cys vs p.Gly12Val; in sample 16, p.Gly12Arg vs p.Gly13Cys; and in sample 18, p.Gly12Asp vs p.Gly13Asp) was not
considered indicative of discrepancy because the precise identity of the mutation present is clinically irrelevant in this case (instances of type-of-mutation
discordance are highlighted with a light background). In cases where the K-ras StripAssay and TheraScreen DxS kit generated inconsistent results, the sample was
considered to be mutated only if one of the other three methods indicated the presence of a mutation. Thus, three samples (samples 20, 21, and 29) generated
inconclusive results. Inconclusive results were excluded from further analysis.
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DxS kit only detected mutation in the NCI-H620 cell
line (p.Gly12Val); the K-ras StripAssay failed to yield any
positive results when analyzed using the StripAssayEvaluator software, but was judged to have correctly
detected a mutation in the NCI-H620 line on the basis
of visual inspection. At a mutant minority of 0.25%, only
the K-ras StripAssay yielded a positive result. Remarkably,







Direct sequencing 6/131 4.5 6/116 5.2
Pyrosequencing 10/131 7.6 10/116 8.7
HRM - - 15/116 13.1
TheraScreen DxS 20/131 15.2 17/116 14.6
K-ras StripAssay 26/131 19.8 24/116 20.7
To allow comparison with HRM, results are provided not only for 131 but also
for 116 samples.
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NCI-H2009 line (p.Gly12Ala) even at a mutant minority of
0.125%.Discussion
We have examined the ability of five different methods
to detect mutations in the KRAS gene in 131 DNA sam-
ples. KRAS mutations were detected in 21 samples
(16.0%), 107 samples were found to contain wild-type
DNA (81.7%), and three yielded inconclusive results
(2.2%) (Table 1). Of the 21 samples in which mutation
was detected by one or more methods, there were only
four for which all five yielded a positive result (19.0%).
Of the 95 wild-type samples analyzed by all five meth-
ods, concordance was observed in 87 (91.6%); overall,
the five methods were in agreement with one-another
for 78% of the samples examined. Excluding HRM, the
four remaining analytical methods all generated positive
results for 4 out of 21 samples found to be positive by
one or more method (4.4%) and all generated negative
results for 101 of 107 samples found to be negative by
one or more method (94.4%), giving an overall agree-
ment of 82%.
Our findings concerning the ability of these methods
to detect mutations in KRAS are similar to those of
Whitehall et al. (2009), who compared Dideoxy sequen-
cing, HRM, the TIB Molbiol kit (Berlin, Germany), and
the TheraScreen DxS (Manchester, UK) kit using DNA
isolated from frozen colorectal cancer tissues. In their
study, all five methods were found to be in concordance
with regard to the KRAS mutation status of 66 of the 80







0/110 (0 %) 0/110 (0 %)
False negatives
(1 - sensitivity)
15/21 (71 %) 11/21 (52 %)Both our results and those obtained by Whitehall [20]
show that a significant number of samples from colorec-
tal tumor and NSCLC contain mixtures of KRAS wild-
type and KRAS mutant cells, and that in many cases the
percentage of mutant cells is below the threshold that
can be detected by direct sequencing. This inherent het-
erogeneity of bioptic tumor tissues is an universal prob-
lem, albeit one that can be partially addressed by
concentrating the tumor cells (e.g. by laser capture
microdissection) before extracting their DNA. However,
the fact that even a pure sample of tumor cells may con-
tain large quantities of wild-type KRAS further compli-
cates the selective identification of mutations in this
gene. Consequently, it is desirable that methods for
detecting KRAS mutations should be highly sensitive,
and this point should be borne in mind when selecting a
proper diagnostic method. Our study identified the
TheraScreen DxS kit as having the best ability to detect
KRAS mutations in clinical samples, followed by the
K-ras StripAssay (Table 4).
Our results also indicate that direct sequencing is only
of limited utility when trying to detect mutations in the
KRAS gene in cancer tissues, since this method only
detected KRAS mutations in 6 of the 131 DNA samples
tested, even though 21 were found to contain mutations
by other methods. Though direct sequencing is still being
advocated as KRAS genotyping method of choice [21], it
missed 72% of all mutations in our cohort. Obviously, the
sensitivity of the sequencing methods could be further
improved by using laser microdissection [22], preferential
preamplification [23], inclusion of both primary and
metastatic tissues in the analysis, or by using clamping to
suppress PCR amplification of the wild-type gene [24].
However, we agree with Pinto et al. that Sanger sequen-
cing (without the first steps of COLD-PCR) [25] is
currently outperformed by more sensitive techniques [26].
Pyrosequencing is easily capable of detecting PCR frag-
ments that are 25–50 bp in length while longer fragments
may pose a problem. However, this is not the case of
detecting mutations in KRAS, because the most frequent
mutations in this gene are adjacent, occurring in codons
12 and 13. It may even be advantageous to use short frag-
ments when diagnosing mutations because DNA may be
fragmented during the processing of clinical tissue sam-
ples. In accordance with results of others [27,28], Pyrose-







0/110 (0 %) 6/110 (5 %) 2/96 (2 %)
1/21 (5 %) 2/21 (10 %) 6/20 (30 %)
Figure 6 Comparative sensitivity analysis of KRAS typing kits in dilution series, where DNA from three mutated cell lines was diluted
in wild-type DNA. Results of dilution series consisted of 25%, 20%, 15%, 10%, 5%, 1%, 0.5%, 0.25%, and 0.125% of mutated DNA in wild-type
DNA. For threshold found in the first dilution experiment and one adjacent concentration from each side, typing was performed three times.
Resulting consensus thresholds (found two or three times out of three repeats) for cell lines A549 (p.Gly12Ser), NCI-H620 (p.Gly12Val), and
NCI-H209 (p.Gly12Ala) are shown in the graph.
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mutant cells ranging from 5 to 25% (Table 4) while
quantification of mutated portion of DNA was not pos-
sible. This is probably due to preferential amplification
of the mutated samples by the primers designed for the
particular Biotage kit used. This shortcoming could be
obviated by a better primer design or other modifica-
tion of the kit and/or improvements in the interpret-
ation algorithm [29,30]. Promisingly, a massively
parallel pyrosequencing system using nanoliter reac-
tion volumes has yielded satisfying results in an inter-
laboratory comparison [28]. While this probably
represents the future of testing in predictive oncology,
such systems are prohibitively costly for most labora-
tories at the present.Table 4 Pairwise concordance between methods for KRAS mu
Direct sequencing TheraScreen D
+ - + -
Direct sequencing + 0.338
-
TheraScreen DxS + 5 15
- 1 110
K-ras StripAssay + 5 21 19 7
- 1 104 1 10
Pyrosequencing + 6 4 9 1
- 0 121 11 11
HRM + 6 9 12 3
- 0 99 4 95
Every intersection of method row and method column corresponds to a 2x2 contin
concordance metrics.HRM proved to be the least expensive and the most rapid
method, as it requires only standard real-time PCR reagents
and a slightly prolonged PCR protocol. Despite the optimis-
tic references from other laboratories [31], the analysis of
the melting profiles in our hands remains less reliable than
other methods, and even repeated testing of our reference
DNA did not always yield consistent results. Because of
this, the typing of two samples by this method was incon-
clusive. We may speculate with Do [32] that treatment of
DNA with uracil glycosylase or special step of DNA clean-
ing would help standardize the method and better its ana-
lytical parameters. Interestingly, HRM analysis identified
mutations in the KRAS locus of two DNA samples (samples
31 and 32) for which none of the other methods detected
any mutation (Table 1). In keeping with the findings oftation detection
xS K-ras StripAssay Pyrosequencing HRM







11 4 9 6
12 87 1 98
gency table for two methods. The upper right part of the table is filled with κ
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http://www.jeccr.com/content/31/1/79other authors [33], we interpret these results as reflecting a
tendency of HRM to generate false positives. However, it is
possible that they reflect rare mutations outside codon 12
and 13 that destabilize heteroduplex DNA even in the pres-
ence of an excess of wild-type DNA. Although cost and
time efficiency are important factors in clinical diagnosis,
the reproducibility of the HRM method will need to be
improved before it can be considered viable. This could po-
tentially be done by changing primers [34], adding melting
standards [35], spiking with oligonucleotides [36], or com-
bination with SNaPshot [37].
The StripAssay was the most analytically sensitive
test (Table 2) of those we examined. On the basis of
the results obtained with this method in the series
of tests conducted with dilution series of mutant
KRAS DNA (Figure 6), one could even argue that
samples 24 to 30 should be reassigned as mutants
(Table 2), thereby changing the false positive rate for
the K-ras StripAssay to 0/128 and the false negative
rate for TheraScreen DxS to 7/128. However, the in-
terpretation of StripAssay results can be quite prob-
lematic for samples whose mutant DNA content is
below 1% (see the result obtained with a mutant mi-
nority of 0.5% NCI-H620 in Figure 6). Insofar, it was
not tested in clinical studies what is a significance of
fraction of mutated cells below 1%, regardless of the
typing method used.
During time of submitting this article, company´s soft-
ware was upgraded to follow more precisely the require-
ments of ISO15189 norm (scanner calibration standard
was added and manual baseline correction feature wasTable 5 Summary of the properties of the different methods
Sanger sequencing Pyrosequencing The
CE mark no no yes
Limit of
detection*
25-30 %* 5-10 %* 1 %
Turnaround
time






6 hrs 4 hrs 2 hr
Amount of
input DNA




Yes – can detect
any mutation located
between the primers.
Yes – can detect any















* from reference of Tsiatis26 and Ogino27.removed). It remains to be seen if such changes bring
any improvement to diagnostic accuracy.
Of the methods examined in this study, the TheraSc-
reen DxS kit was the fastest method and exhibited the
highest sensitivity and specificity. However, it was also
the most expensive method that is not free of false reac-
tions. Specifically, the kit failed to detect the p.Gly13Cys
mutation in sample 2 because it is not designed to detect
this mutation. Although the frequency of the mutations
that are not covered by the TheraScreen DxS test is very
low and clinically not highly relevant, this nevertheless
constitutes an inherent limitation of the kit. In addition,
the precise allelic mutation detected by this kit in sam-
ples 3, 16, and 18 differed from the consensus result.
While this could potentially be due to stochastic vari-
ation in the early events of PCR priming, there is no
firm evidence to support this hypothesis. Although dis-
crepancies in the precise identity of the mutation are not
yet clinically relevant, and these results were not scored
as errors in this study, this finding warrants caution
when using the ARMS Scorpions assay in different diag-
nostic setups, where the type of mutation is important
(e.g. when looking at the T790M and S768I activating
mutations in EGFR genotyping). As discussed above,
samples 24 to 30 gave positive results in the StripAssay
but were negative when analyzed with the TheraScreen
DxS kit, and they seem to have a mutant population in
the clinically “grey area,” having less than 1% of the cells
in the sample containing KRAS mutation. Ideally, their
status should have been resolved by PCR amplicon clon-
ing, followed by sequencing of the clones, digital PCR,raScreen DxS StripAssay HRM
yes no CE mark
below 1 % 5-10 %* Limit of
detection*
day 1 day 1/2 day Turnaround
time
medium difficult Ease of
interpretation
s 5 hrs 2 hrs Technician
time
















€ 60 € 4 € Reagent cost
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http://www.jeccr.com/content/31/1/79or ultradeep sequencing. However, this approach is not
practical for routine work and we did not have sufficient
DNA to perform this experiment. Moreover, the low fre-
quency of KRAS mutations in patient tumors have un-
known clinical relevance, since all drug registration trials
were performed using 1% of mutant KRAS cells as a low
detection limit of the method.
The properties of the different methods examined in this
work are summarized in Table 5.
We agree with Tsiatis et al. [27] that for research pur-
poses more than one genotyping platform is necessary
to reveal double mutations and to provide complemen-
tary data. In clinical settings, the most readily accessible
NSCLC sample type is needle or brush biopsy, which is
examined cytologically while resected, or biopsied tumors
processed by formaldehyde fixation and paraffin embed-
ding (FFPE). Proportion of FFPE samples from all samples
usually reflects the best local practice and experience. Un-
fortunately, the FFPE process alters significantly the quality
of DNA, and in many cases the DNA isolation from cy-
tology smears yields higher quality albeit lower quantity of
DNA.Very low quantity of available DNA isolated from
cytological preparations was a major limiting factor in our
comparative study, which we tried to overcome using fro-
zen tissue from biobank, since it provides both high quality
and quantity of DNA. Moreover, due to recent biobanking
initiatives [38], we are more frequently facing situations,
where the tumor molecular diagnostics is performed from
frozen tissues. Of the 11 FFPE samples genotyped using
both the StripAssay and TheraScreen, 5 samples could not
be typed by at least one method, 2 samples were wildtype
by both methods, 3 samples were mutant by both methods,
and one sample was p.Gly12Asp by TheraScreen and wild-
type by StripAssay. From one point of view, it could be
argued that our genotyping results obtained using frozen
samples are transferable to genotyping of FFPE samples be-
cause the mechanisms by which the methods work are not
dependent on the nature of the input sample. On the other
hand, it should be noted that improperly-performed paraf-
fin embedding damages DNA and can favor methods that
are more robust to variation in the amount and quality of
the starting material (this would arguably disfavor TheraSc-
reen because it requires eight PCR reactions whereas the
other methods require only one equivalent reaction). It has
been suggested that the issue of limited material for testing
can be largely circumvented by using whole genome ampli-
fication techniques [39,40], although the potentially biasing
impact of the genome amplification techniques on low fre-
quency somatic mutation genotyping is still not fully
addressed. However, we suppose that our tests of kit
performance on frozen tissue samples provide useful
insights into their general utility and will be valuable
for orchestrating genotyping efforts across molecular
pathology laboratories.Conclusions
The performance of five methods (Direct sequencing, Pyro-
sequencing, High resolution melting analysis, the TheraSc-
reen DxS kit, and the K-ras StripAssay) for detecting
mutations in the KRAS gene was compared using DNA
extracted from 131 frozen NSCLC samples. The TheraSc-
reen DxS kit was found to be the most effective, followed
by the StripAssay kit. However, because of the heterogen-
eity of typical cancer tissue samples and the differences in
the two methods’ mechanisms of action, there are still un-
satisfactory numbers of discrepancies between these two
‘best’ methods, which failed to agree on 8 of the 131 speci-
mens examined in this work. Nevertheless, our findings
should facilitate the rational selection of methods for
detecting mutations at the KRAS locus using heterogeneous
clinical samples obtained from biopsies of cancer patients.
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